Ablative Therapy of Oligometastatic Tumor After Response to Conventional First Line Treatment

Inclusion Criteria

• •1. Performance status 0 or 1 on the Eastern Cooperative Oncology Group (ECOG).
• •2. Histologically diagnosis of one of these tumour types:
• •1. Hormone receptor positive, HER2 negative breast cancer
• •2. Triple negative breast cancer
• •3. HER2+ breast cancer
• •4. Non small cell lung cancer without oncogenic addiction
• •5. Head and Neck squamous cell carcinoma without recurrence in the radiation field
• •6. Gastric adenocarcinoma
• •7. Esophageal cancer (adenocarcinoma or epidermoid carcinoma)
• •8. Recurrent pancreatic cancer without local recurrence
• •9. Anal cancer
• •10. Bladder cancer
• •11. Clear cells renal cell carcinoma
• •12. Prostate cancer sensitive to castration
• •13. Adenocarcinoma endometrial cancer
• •14. Epidermoid carcinoma or adenocarcinoma of the cervix
• •15. Colorectal cancer
• •16. Recurrent Soft Tissue Sarcoma
• •17. Melanoma
• •3. Patient with a decision by the local team to give OST and effective administration of OST. OST is defined as the most efficient choice in terms of survival in first line of advanced disease according to ESMO or other international guidelines. In case of multiple choice as first line, if no data provided direct evidence of superiority from one or the other options, there are all considered as OST. If the patient received a less efficient treatment because of his comorbidity or frailty, the eligible criteria won't be fulfilled.
• •4. Have non-progressive disease after 3 to 6 months of treatment, and less than 6 weeks before presentation to the multidisciplinary team
• •1. Patients with complete response and no target lesion are excluded.
• •2. Patients with bone metastasis with remaining bone condensation or scare from tumoral activity may be eligible depending on metabolic activity of the lesion or local multidisciplinary committee decision concerning the risk of residual disease.
• •5. After 3 to 6 months of treatment, and less than 6 weeks before start of LAT, patient must have an oligometastatic disease defined as all lesions (including primitive lesion) amenable to local ablative treatment according to local investigator team and respective local committee.